journal article·2016-07-03Open access

Swelling, mechanical strength, and release properties of probucol microcapsules with and without a bile acid, and their potential oral delivery in diabetes

Rebecca Negrulj, Armin Mooranian, Nigel Chen-Tan, Hesham S Al-Sallami, Momir Mikov, Svetlana Golocorbin-Kon, Marc Fakhoury, Gerald F. Watts, Frank Arfuso, Hani Al-Salami

Abstract

We have demonstrated a permeation-enhancing effect of deoxycholic acid (DCA), the bile acid, in diabetic rats. In this study, we designed DCA-based microcapsules for the oral delivery of the antilipidemic drug probucol (PB), which has potential antidiabetic effects. We aimed to further characterize these microcapsules and examine their pH-dependent release properties, as well as the effects of DCA on their stability and mechanical strength at various pH and temperature values. Using the polymer sodium alginate (SA), we prepared PB-SA (control) and PB-DCA-SA (test) microcapsules. The microcapsules were examined for drug content, size, surface composition, release, Micro-CT cross-sectional imaging, stability, Zeta potential, mechanical strength, and swelling characteristics at different pH and temperature values. The microencapsulation efficiency and production yield were also examined. The addition of DCA resulted in microcapsules with a greater density and with reduced swelling at a pH of 7.8 and at temperatures of 25°C and 37°C (p < 0.01). The size, surface composition, production yield, and microencapsulation efficiency of the microcapsules remained similar after DCA addition. PB-SA microcapsules produced multiphasic PB release, while PB-DCA-SA microcapsules produced monophasic PB release, suggesting more controlled PB release in the presence of DCA. The PB-DCA-SA microcapsules showed good stability and a pH-sensitive uniphasic release pattern, which may suggest potential applications in the oral delivery of PB in diabetes.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Advanced Drug Delivery Systems · Drug Solubulity and Delivery Systems · Advancements in Transdermal Drug Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Biotechnology and Drug Development Research Laboratory, School of Pharmacy, Curtin Health Innovation Research Institute, Biosciences Research Precinct, Curtin University, Perth, Western Australia, Australia

Faculty of Science & Engineering, Curtin University, Perth, Western Australia, Australia

School of Pharmacy, University of Otago, Dunedin, New Zealand

Department of Pharmacology, Toxicology and Clinical Pharmacology, Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia

Department of Pharmacy, Faculty of Medicine, University of Montenegro, Podgorica, Montenegro

Faculty of Medicine, University of Montreal, Montreal, Quebec, Canada

School of Medicine and Pharmacology, Royal Perth Hospital, University of Western Australia, Perth, Western Australia, Australia

Stem Cell and Cancer Biology Laboratory, School of Biomedical Sciences, Curtin Health Innovation Research Institute, Biosciences Research Precinct, Curtin University, Perth, Western Australia, Australia

References (30)

Show source-provided references
1. 10.1007/BF0319102610.1007/BF03191026 ↗
2. 10.1007/BF0319138310.1007/BF03191383 ↗
3. 10.1007/s13318-011-0060-y10.1007/s13318-011-0060-y ↗
4. 10.1358/mf.2008.30.2.115965210.1358/mf.2008.30.2.1159652 ↗
5. 10.1358/mf.2008.30.2.115965210.1358/mf.2008.30.2.1159652 ↗
6. 10.1111/j.1753-5174.2008.00006.x10.1111/j.1753-5174.2008.00006.x ↗
7. Al-Salami H · Drug Metabolism Reviews · 2008 · 40 · 81
8. 10.1111/j.1753-5174.2008.00006.x10.1111/j.1753-5174.2008.00006.x ↗
9. Al-Salami H · The New Zealand Pharmacy Journal · 2007 · 27 · 17
10. 10.1148/radiol.1110160810.1148/radiol.11101608 ↗
11. 10.1016/j.biomaterials.2012.03.00810.1016/j.biomaterials.2012.03.008 ↗
12. Calasan J · Febs Journal · 2012 · 279 · 267
13. 10.1016/j.jconrel.2006.04.01710.1016/j.jconrel.2006.04.017 ↗
14. 10.1016/j.carbpol.2011.11.01210.1016/j.carbpol.2011.11.012 ↗
15. 10.1155/2013/59860310.1155/2013/598603 ↗
16. Mikov M · . Potentials and Limitations of Bile Acids and Probiotics in Diabetes Mellitus · 2012
17. 10.1007/BF0319111010.1007/BF03191110 ↗
18. Mikov M · Febs Journal · 2006 · 273 · 210
19. 10.1007/BF0319098410.1007/BF03190984 ↗
20. 10.1208/s12249-014-0205-910.1208/s12249-014-0205-9 ↗
21. Mooranian A · Artif Cells Nanomed Biotechnol · 2014 · 11 · 1
22. Mooranian A · Drug Des Devel Ther · 2014 · 8 · 1003
23. Mooranian A · Drug Des Devel Ther · 2014 · 8 · 1221
24. 10.1007/s12247-014-9182-510.1007/s12247-014-9182-5 ↗
25. Mooranian A · Pharm Dev Technol · 2014 · 0 · 1
26. Negrulj R · J Endocrinol Diabet Mellitus · 2013 · 1 · 49
27. 10.3109/10837450.2010.50289810.3109/10837450.2010.502898 ↗
28. 10.1016/j.biomaterials.2005.05.00710.1016/j.biomaterials.2005.05.007 ↗
29. 10.1007/s10620-012-2335-910.1007/s10620-012-2335-9 ↗
30. 10.1016/j.atherosclerosis.2009.04.00210.1016/j.atherosclerosis.2009.04.002 ↗